Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Zydelig (idelalisib by Year
Zydelig (idelalisib — hematologic oncology, legacy breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Zydelig (idelalisib: $1M in FY2021, down 50.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
Source: Form 10-K (filed 2022-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zydelig (idelalisib — hematologic oncology, legacy breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 1 | -50.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 2 | 0.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 2 | 0.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 2 | -33.3% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 3 | +200.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Zydelig (idelalisib ($M), annual FY2016–FY2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-zydelig-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.